Future oncology (London, England)
Characteristics and outcomes of patients with HCC treated with atezolizumab/bevacizumab, stratified by second line therapy.
Amit G Singal, Kirhan Özgürdal, Zdravko Vassilev, Federica Pisa, William S John, Taavy A Miller, Prathamesh Pathak, Sarah Gordon, Bruce Feinberg, Xiaoyun Pan
Published: 202610.1080/14796694.2026.2614306
Abstract
BACKGROUND: Atezolizumab plus bevacizumab (atezo+bev) is a standard-of-care 1L treatment for unresectable hepatocellular carcinoma (uHCC). Understanding its adoption and use, clinical outcomes, and subsequent therapies are needed. METHODS: This retro…
Preview only. Read the full abstract at the source